Advances in targeted therapy and immunotherapy for esophageal cancer.

Chin Med J (Engl) · 2023 · PMC10431250 · PMID 37403208

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 31 ] Based on the results of LEOPARD-2 (80.9% ESCC), cetuximab plus radiochemotherapy showed a trend toward improved PFS and metastasis-free survival (MFS) for unresectable EC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.